TBPH Stock — Theravance Biopharma, Inc.

Theravance Biopharma, Inc. (TBPH)

Updated September 25, 2026.

TBPH is a Stock. Total return is -25.8% over the past 12.4 years, 431.1 points behind SPY at 405.3%.

Theravance Biopharma is a biopharmaceutical company that develops and commercializes medicines for respiratory and neurological conditions, including YUPELRI, an inhaled treatment for chronic obstructive pulmonary disease, and Ampreloxitene, an investigational therapy in late-stage clinical trials for neurogenic orthostatic hypotension. The company does not currently have an established distribution schedule. Theravance Biopharma may appeal to investors seeking exposure to early-stage pharmaceutical development, though it carries the inherent risks of clinical-stage drug development and commercialization in a competitive healthcare sector.

TBPH performance versus SPY

Price and return data through 2026-09-25.

Total return is -25.8% over the past 12.4 years, 431.1 points behind SPY at 405.3%. Over the past year its total return — price change plus distributions reinvested — is 23.5%. Its deepest 1-year drawdown was 34.6%.

TBPH key facts

Asset type

Stock

Asset class

Equity

Distribution frequency

None

Last close

$17.03 (stale; as of 2026-09-25)

Market cap

$884,176,381

Average volume

0.0

Beta

0.245

Payout ratio

0.0%

P/E ratio

16.38

Forward P/E

9.7276

EPS

$1.04

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

TBPH risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 34.6%.

Who may consider TBPH — and who may not

It is a weaker fit for investors who need monthly cash flow (TBPH does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on TBPH

• All tickers starting with T

Tagged: Healthcare, Small Caps.

Frequently asked questions